Table 1 Projected Clinical Events per Patient and over Patient Lifetime in the United Kingdom
From: Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation
Events over patient lifetime per patient | Aspirin | Dabigatran 150 mg | Rivaroxaban 20 mg | |
|---|---|---|---|---|
Total ischaemic stroke events | 0.08788 | 0.06151 | 0.06151 | |
Δ DOAC vs. Aspirin (Negative = Reduction; Positive = Increase) | − 0.02636 | − 0.02636 | ||
% DOAC vs. Aspirin (Negative = Reduction; Positive = Increase) | − 30% | − 30% | ||
Total bleeding events | 0.91371 | 1.09226 | 1.21246 | |
Δ DOAC vs. Aspirin | 0.17855 | 0.29875 | ||
% DOAC vs. Aspirin | 20% | 33% | ||
Haemorrhagic stroke | 0.02292 | 0.01432 | 0.02360 | |
Δ DOAC vs. Aspirin | − 0.00859 | 0.00069 | ||
% DOAC vs. Aspirin | − 38% | 3% | ||
Other ICH | 0.01549 | 0.01007 | 0.01596 | |
Δ DOAC vs. Aspirin | − 0.00542 | 0.00046 | ||
% DOAC vs. Aspirin | − 35% | 3% | ||
ECH and CRNM bleeds | 0.87530 | 1.06787 | 1.17290 | |
Δ DOAC vs. Aspirin | 0.19257 | 0.29760 | ||
% DOAC vs. Aspirin | 22% | 34% | ||
Total events | 1.00159 | 1.15377 | 1.27397 | |
Δ DOAC vs. Aspirin | 0.15218 | 0.27238 | ||
% DOAC vs. Aspirin | 15% | 27% | ||